Autres langues Prelude Therapeutics Incorporated

Actions

PRLD

US74065P1012

Temps Différé Nasdaq Autres places de cotation 18:08:25 07/05/2024			Varia. 5j.	Varia. 1 janv.
3,79 ^USD	-1,04 %		+0,53 %	-11,24 %

13:20	Prelude Therapeutics Incorporated annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
10/04	Bryant D. Lim occupera les fonctions de directeur financier et de directeur comptable de Prelude Therapeutics Incorporated	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Prelude Therapeutics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	13:20
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update	13:01
Bryant D. Lim to Serve as Principal Financial Officer and Principal Accounting Officer of Prelude Therapeutics Incorporated	10/04
Prelude Therapeutics Incorporated Announces Chief Financial Officer Changes	10/04
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting	09/04
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting	05/03
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference	29/02
Prelude Therapeutics Shares Surge Following Shelf Registration	16/02
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024	15/02
Prelude Therapeutics Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023	15/02
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) dropped from NASDAQ Biotechnology Index	15/12
Prelude Therapeutics Incorporated announced that it has received $24.999997 million in funding	13/12
Prelude Therapeutics Announces $25 Million Private Placement	11/12
Prelude Therapeutics Incorporated : Announces $25 Million Private Placement - Form 8-K	11/12
Prelude Therapeutics Incorporated announced that it expects to receive $24.999997 million in funding	11/12
Prelude Therapeutics Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	01/11
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results	01/11
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology	01/11
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology	01/11
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference	14/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Prelude Therapeutics Incorporated

Actions

PRLD

US74065P1012

Autres langues

Filtres